These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1159 related articles for article (PubMed ID: 34791293)

  • 1. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
    Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory pathways of importance for management of inflammatory bowel disease.
    Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
    World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review.
    Alimohammadi N; Koosha F; Rafeian-Kopaei M
    Curr Pharm Des; 2020; 26(22):2668-2675. PubMed ID: 32250220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
    Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
    Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
    Bhat MA; Usman I; Dhaneshwar S
    Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
    Liu J; Di B; Xu LL
    Cytokine Growth Factor Rev; 2023; 71-72():1-12. PubMed ID: 37455149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases.
    Yoo JH; Donowitz M
    World J Gastroenterol; 2019 Aug; 25(30):4125-4147. PubMed ID: 31435168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical and recent advances in the treatment of inflammatory bowel diseases.
    Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
    Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets for inflammatory bowel disease.
    Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
    J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
    Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
    World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current scenario in inflammatory bowel disease: drug development prospects.
    Chandel S; Prakash A; Medhi B
    Pharmacol Rep; 2015 Apr; 67(2):224-9. PubMed ID: 25712643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease.
    Sukocheva OA; Lukina E; McGowan E; Bishayee A
    Adv Protein Chem Struct Biol; 2020; 120():123-158. PubMed ID: 32085881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.
    de Mattos BR; Garcia MP; Nogueira JB; Paiatto LN; Albuquerque CG; Souza CL; Fernandes LG; Tamashiro WM; Simioni PU
    Mediators Inflamm; 2015; 2015():493012. PubMed ID: 26339135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease.
    Rivera Rodríguez R; Johnson JJ
    Pharmacol Ther; 2023 Aug; 248():108456. PubMed ID: 37247693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation.
    Shao BZ; Wang SL; Pan P; Yao J; Wu K; Li ZS; Bai Y; Linghu EQ
    Inflammation; 2019 Aug; 42(4):1147-1159. PubMed ID: 30937839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.